1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Stemcell Holdings, Inc.

Stemcell Holdings, Inc.

STMM
Stemcell Holdings, Inc.US flagOther OTC
0.06
USD
-NaN
- -
1.64MMarket Cap
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
0.12
0.22
0.36
Basic EPS, GAAP
- -
0.05
0.09
0.11
Free Cash Flow per Basic Share
- -
0.1
0.07
0.08
Dividend per Share
- -
- -
- -
- -
Book Value per Share
- -
0.05
0.14
0.22
Tangible Book Value per Share
- -
0.05
0.14
0.22
Basic Weighted Avg Shares
- -
28
28
27
Sales/Revenue/Turnover
- -
3
6
10
Operating Margin (%)
- -
79.43
58.25
48.03
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
- -
1
2
3
Effective Tax Rate (%)
- -
47.18
33.03
35.42
Profit Margin (%)
- -
42
38.99
31.04
Working Capital
- -
1
3
4
LT Debt
- -
- -
- -
- -
Total Equity
- -
1
4
6
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
51.99
92.5
67.34

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
27
27
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
6
8
10
Cash, Cash Equivalents & STI
4
5
5
Accounts Receivable, Net
- -
1
2
Inventories
- -
- -
- -
Total Current Liabilities
3
5
6
Payables & Accruals
3
5
6
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
179.78%
Free Cash Flow
- -
- -
-31.69%
Net Income, GAAP
- -
- -
71.82%
Sales/Revenue/Turnover
- -
- -
85.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
1
2
3
2017
1
2
2
2
6
2018
2
3
3
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.01
0.01
0.03
- -
0.05
2017
0.01
0.03
0.02
- -
0.09
2018
0.03
0.02
0.04
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Takaaki Matsuoka
Full Time Employees
28
Sector
Healthcare
Industry
Biotechnology
Address
5-9-15-3F, Minamiaoyama Tokyo Japan 107-0062
IPO Date
Jul 15, 2020
Website
stemcell-holdings.com
Similar Companies
Vanda Pharmaceuticals Inc. (VNDA)
Zogenix, Inc. (ZGNX)
Aadi Bioscience, Inc. (AADI)
Karolinska Development AB (publ) (KDEV.ST)
Exelixis, Inc. (0IJO.L)
Ginkgo Bioworks Holdings, Inc. (DNA)
Business
Stemcell Holdings, Inc. (STMM) operates as a holding company focused on regenerative medicine, primarily through its subsidiary Stemcell Co., Ltd., providing stem cell therapies including autologous adipose-derived mesenchymal stem cells (ADMSC) and natural killer (NK) cell treatments; biotechnology consulting services specializing in cross-border partnerships between the United States and Japan; and technical assistance for culturing, storing, delivering stem cells, along with related administrative support. The company facilitates intellectual property management, licensing agreements, patent strategies, investment opportunities, and regulatory bridging in biopharmaceuticals and regenerative medicine sectors, targeting medical research, pharmaceuticals, and healthcare services with operations centered in Tokyo, Japan, and connections to global biotech entities. Founded prior to its public listing and headquartered in the United States with key activities in Japan, Stemcell Holdings serves customers in research institutions, clinics, and biopharma firms across North America, Asia, and international markets. In recent developments, the company has emphasized expansion in stem cell regenerative therapies amid a dynamic market, with no major acquisitions, funding rounds, or partnerships publicly announced in 2024 or 2025; it maintains a niche role in enabling collaborations for therapeutic advancements in diseases treatable by stem cells and NK therapies.